-
BioCardia NasdaqCM:BCDA BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. The company's lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia. It is also developing an allogeneic cells therapy platform, which is an investigational culture expanded bone marrow derived mesenchymal cell therapy in Phase I/II trial to treat ischemic heart failure and acute respiratory distress syndrome. In addition, the company offers the Helix biotherapeutic delivery system for minimally invasive targeted delivery of biologic agents to the heart; and Morph deflectable guides and sheaths products. It has collaboration agreements with CellProthera in the development of ProtheraCytes, which is currently under Phase II trial for the treatment of acute myocardial infarction. BioCardia, Inc. is based in Sunnyvale, California.
Location: 320 Soquel Way, Sunnyvale, CA, 94085, United States | Website: https://www.biocardia.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
11.33M
Cash
949K
Avg Qtr Burn
-2.029M
Short % of Float
3.92%
Insider Ownership
21.61%
Institutional Own.
4.75%
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
BCDA-02 CardiAMP cell therapy Details Heart failure, Myocardial ischemia | Phase 3 Data readout | |
BCDA-01 CardiAMP cell therapy Details Ischemic stroke, Heart failure | Phase 3 Update | |
BCDA-03 CardiALLO cell therapy Details Ischemic stroke, Heart failure | Phase 1/2 Data readout |